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Abstract
Background: There is increasing evidence that structural lung changes may be present before the occurrence of airflow
limitation as assessed by spirometry. This study investigated the prevalence of computed tomography (CT) quantified
emphysema, airway wall thickening and gas trapping according to classification of airflow limitation (FEV1/FVC ,70% and/
or , the lower limit of normal (LLN)) in (heavy) smokers.
Methods: A total number of 1,140 male former and current smokers participating in a lung cancer screenings trial (NELSON)
were included and underwent chest CT scanning and spirometry. Emphysema was quantified by the 15th percentile, air way
wall thickening by the square root of wall area for a theoretical airway with 10mm lumen perimeter (Pi10) and gas trapping
by the mean lung density expiratory/inspiratory (E/I)-ratio. Participants were classified by entry FEV1/FVC: group 1.70%;
group 2,70% but .LLN; and group 3,LLN. 32 restricted subjects, i.e. FEV1/FVC .70% but FEV1 ,80% predicted, were
excluded. Multivariate regression analysis correcting for covariates was used to asses the extent of emphysema, airway wall
thickening and gas trapping according to three groups of airflow limitation.
Results: Mean (standard deviation) age was 62.5 (5.2) years and packyears smoked was 41.0 (18.0). Group 2 subjects when
compared to group 1 had a significantly lower 15th percentile,2920.6 HU versus 2912.2 HU; a higher Pi10, 2.87 mm versus
2.57 mm; and a higher E/I-ratio, 88.6% versus 85.6% (all p,0.001).
Conclusion: Subjects with an FEV1/FVC,70%, but above the LLN, have a significant greater degree of structural lung
changes on CT compared to subjects without airflow limitation.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
important causes of morbidity and mortality worldwide and its
mortality rates are still rising. [1] Paradoxically, it still is being
under diagnosed. [2] COPD is characterized by the presence of
airflow limitation, i.e. when the forced vital capacity (FVC) to the
forced expiratory volume in one second (FEV1) -ratio is below a
predefined threshold and currently spirometry is used to diagnose
COPD. [3]
The airflow limitation is the result of several structural changes
in the lung like destruction of airway parenchyma (emphysema)
and small airway disease (gas trapping and airway wall thickening).
[4] Computed tomography (CT) of the chest is used to quantify
the extent of these structural changes. [5] Assessing the degree of
these structural changes can give a better insight in the
background of airflow limitation in individual subjects and assess
the heterogeneity of the disease. There is evidence that these
structural changes already are present before airflow limitation is
present.
While the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) propose a fixed value of FEV1/FVC ,70% as
cut-off for diagnosing airflow limitation others advocate the lower
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limit of normal (LLN). [3] Both methods have their merits and
flaws and currently no there is no consensus on which to use. [6]
Unfortunately, in the absence of a real gold standard of COPD a
consensus is an ideal state not to be reached soon. [7].
Opponents of the fixed ratio believe that a ratio of 70% results
in overdiagnosis. In this study we therefore examined the degree of
structural changes in the lung, emphysema, airway wall thickness
and gas trapping, by CT in a cohort of relatively healthy male
smokers according to their FEV1/FVC. Subjects were classified as
having no airflow limitation (FEV1/FVC .70%), in-between
(FEV1/FVC ,70%, but .LLN) and airflow limitation (FEV1/
FVC ,LLN). We hypothesized that the in-between group had
significantly more structural airway changes on CT than those
without airflow limitation.
Methods
Ethics Statement
The ethics committees of the involving hospitals (University
Medical Center Utrecht and University Medical Center Gronin-
gen, the Netherlands, IRB approval number 03/040) as well as the
Dutch Ministry of Health approved the study. The NELSON trial
is registered at www.trialregister.nlwith trial number
ISRCTN63545820.
Subjects
This study was conducted as a sub study of the Dutch and
Belgium Lung Cancer Screening Trial (NELSON trial –
ISRCTN63545820, registered at www.trialregister.nl). Details of
the selection procedure have previously been described. [8] In
short, participants in the lung cancer screening trial were 50–
75 year old current or former smokers with a smoking history of at
least 16 cigarettes/day for 25 years or at least 11 cigarettes/day for
30 years (.16.5 pack-years). [9] Former smokers should not have
quitted for more than 10 years at inclusion. Detailed smoking
characteristics and symptoms were obtained through a question-
naire. The questionnaire contained the following question on
respiratory symptoms: do you have experienced the following
symptoms cough, sputum expectoration, wheezing or dyspnea for
at least 3 months during the past year, even when you did not
have a cold? To further study COPD an expiratory acquisition
was added to the screening protocol in the University Medical
Center Utrecht, the Netherlands. The NELSON trial was
approved by the Ministry of Health of The Netherlands and the
institutional ethical review board. Written informed consent was
obtained in all screening trial participants.
Pulmonary function testing
Details on the pulmonary function tests (PFT) have been
reported in detail before and included spirometry and body
plethysmography. [10] PFT were obtained according to European
Respiratory Society/American Thoracic Society (ERS/ATS)
guidelines and was performed with ZAN equipment (ZAN
Messgera¨te GmbH, Germany). [11] No broncho dilatation was
applied. Measurements include forced expiratory volume in one
second (FEV1), forced vital capacity (FVC), mid expiratory flow at
50% of FVC (MEF50), residual volume (RV), total lung capacity
(TLC) and the transfer coefficient for carbon monoxide (Kco) as a
measure of lung diffusion capacity. Lower limits of normal were
calculated using the reference equations of the European
Community of Coal and Steel (ECCS). [12] RV/TLC was
expressed as a percentage.
CT scanning
The CT protocol has been described in detail before. [8,13] In
short, all CTs were performed without intravenous contrast
injection, and obtained with 1660.75 mm collimation on the same
scanner (Brilliance 16P, Philips Medical Systems, USA). Volumet-
ric inspiratory and end-expiratory CT scans were obtained after
standardized breathing instructions in all subjects. Subjects
weighing 80 kg or less were scanned with 120 kVp at 30 mAs
for inspiratory acquisition and 90 kVp at 20 mAs for expiratory
acquisition (total effective dose 0.98 and 0.27 mSv, respectively).
Axial images were reconstructed from lung bases to lung apices at
a slice thickness of 1.0 mm at 0.7 mm increment, using a
smoothed reconstruction filter (B-filter, Philips).
Quantitative CT assessment of the lung parenchyma
As previously described, briefly, the lungs were automatically
segmented from the chest wall, airways and mediastinum using
dedicated software. [14] A noise reduction filter was applied to
decrease the influence of noise on the quantitative measurements.
[15] CT emphysema was defined as the percentage of voxels
below Hounsfield Unit (HU) 2950 and the 15th percentile
(Perc15). The Perc15 is the HU number below which 15% of
voxels are distributed and a lower Perc15, i.e. more close to
21000 HU, points at more emphysema. Because the percentage
of voxels below HU 2950 is not normally distributed it is log-
transformed (log950%). CT gastrapping was defined as the
expiratory mean lung density in HU divided by the inspiratory
mean lung density expressed as a percentage (E/I-ratio).
Quantitative CT assessment of large airways
The airway lumen was automatically segmented. [16] Airway
cross-sections are defined perpendicular to the local airway
direction at a spacing of 1mm across all airway centerlines and
inner and outer airway wall borders are segmented for each of
these cross-sections. [17] Obviously failed airway wall segmenta-
tions and cross-sections were automatically discarded from further
analysis. A linear regression of the square root of wall area versus
the lumen perimeter was calculated for the remaining cross-
sections and the square root of wall area for a theoretical airway
with 10mm lumen perimeter (Pi10) was calculated which was used
as measurement of airway wall thickness. [18] For each CT scan a
random selection of cross-sections of the detected airway wall
borders was visually inspected to verify measurement accuracy.
Cases with unsatisfactory results were left out of the airway
analysis.
Data analysis
Descriptive statistics are presented as mean 6 standard
deviation (SD) for normally distributed variables and as median
and inter-quartile range (IQR) for non-normally distributed
variables. Distribution of normality was visually checked by
probability plots. Univariate analyses were done with Students’
T-tests and chi-squared tests, respectively for normal and non-
normal distributed variables. The group without airflow limitation
(i.e. FEV1/FVC .70%) was used as reference. The degree of
structural lung changes at CT (emphysema, gas trapping and
airway wall thickening) were analyzed by analysis of covariance
with class of airflow limitation (FEV1/FVC .70%; ,70% and
.LLN; and ,LLN) as main explanatory variable. Again the
group FEV1/FC.70% was used as reference. Adjustments were
made for age, height, BMI, packyears, smoking status (current or
former) and presence of respiratory symptoms. A p-value of ,0.05
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was considered significant. All statistical analyses were performed
using SPSS 18 (SPSS, Chicago, USA).
Results
Demographics
Subjects’ demographics for the total population and according
to airflow limitation, i.e. FEV1/FVC .70%; ,70%, but .LLN,
and ,LLN, are presented in Table 1. A number of 1,140 males
with were included. Of these 1,140 subjects, 32 had a restrictive
lung function pattern, i.e. FEV1/FVC . 70% but FEV1 ,80%
predicted, which were excluded resulting in 1,108 subjects
included in the current study. Mean (SD) age was 60.4 (19.9) years
and mean (SD) packyears was 41.0 (18.0).Approximately half had
quit smoking (47.2%). The majority had no airflow limitation
according to either the fixed value of FEV1/FVC ,70% or
,LLN (671, 61%). A number of 216 subjects had an FEV1/FVC
,70%, but .LLN, and 221 subjects had airflow limitation
according to both thresholds.
Lung function and clinical variables
Subjects without airflow limitation had smoked less packyears
and more likely had quit smoking, p,0.001. BMI was significantly
lower in subjects with airflow limitation according to either
threshold of FEV1/FVC, all p,0.001. Respiratory symptoms
were significantly more prevalent in subjects with an FEV1/FVC
,70%, but .LLN and ,LLN compared to subjects without
airflow limitation, all p,0.001. Subjects with a FEV1/FVC
,70%, but .LLN had a significantly lower lung diffusion
capacity compared to those without airflow limitation, p = 0.001.
See Table 1.
Structural CT changes
The degree of emphysema, airway wall thickening and gas
trapping for the total population and according to airflow
limitation classification are provided in Table 2. In univariate
analysis subjects with a FEV1/FVC ,70%, but .LLN had a
lower Perc15, higher Pi10 and higher E/I-ratios measure
compared to those without airflow limitation, p,0.001 (Table 2).
Also in the multivariate analysis with correction for age, height,
BMI, packyears, smoking status and presence of respiratory
symptoms a difference in emphysema, airway wall thickening and
gas trapping remained between subjects without airflow limitation
and those with a FEV1/FVC ,70%, but .LLN, all p,0.001.
Subjects with an FEV1/FVC,70%, but .LLN had a mean (95%
confidence interval) 8.1 (210.9–25.3) lower Perc15, a 0.22 mm
(0.14–0.29) higher Pi10 and a 3.25% (2.32–4.27) higher E/I-ratio
compared to subjects without airflow limitation, see Table 3.
In an additional analysis airway wall thickness and gas trapping
measures were added to the analysis of covariance for analyzing
differences in emphysema between the three groups of airflow
limitation. Consequently, emphysema and gastrapping measures
were also added to the analysis for differences in airway wall
thickness, and emphysema and airway wall thickening were added
to the analysis for differences in gas trapping. Again, subjects with
a FEV1/FVC ,70%, but .LLN had more emphysema, airway
wall thickening and gas trapping on CT than those without airflow
limitation, all p,0.001.
Discussion
In this study we showed that former and current smokers with
an FEV1/FVC below 70%, but above the LLN, have significantly
lower diffusion capacity, more emphysema, airway wall thickening
Table 1. Baseline demographics, clinical variables and pulmonary function for the total population and stratified by classification
of airflow limitation.
Total, n =1,108 FEV1/FVC .70%, n=671
FEV1/FVC ,70%, but.LLN,
n =216
FEV1/FVC ,70%, and ,LLN,
n =221
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age [years] 62.5 (5.2) 62.1 (5.1) 63. 7 (5.6)
ˆ
62.8 (5.4)
ˆ
Packyears 41.0 (18.0) 39.9 (17. 7) 41.7 (17.6)
ˆ
43.7 (19.3)#
Current smoker, % (n) 52,8 (585) 49,2 (330) 54,2 (117)# 65,6 (145)#
Weight [kilo] 86.3 (13.1) 88.2 (12. 9) 84.4 (11.9)# 82.0 (13.8)#
Height [centimeters] 178. 5 (6.6) 178.4 (6.4) 178.5 (6.8) 178.5 (7.03)
BMI [kg*m22] 27,1 (3,6) 27. 7 (3.5) 26.5 (3.3)
ˆ
25.8 (3.7)#
FEV1 % pred 94. 8 (17.6) 103.9 (12.4) 92.0 (12.7)
# 75.0 (17.5)#
FEV1/FVC % 70. 9 (9.3) 76.5 (4.4) 67.4 (1. 9)
# 56.4 (7.9)#
MEF50 % pred 68.8 (29.3) 84.9 (23.9) 53.5 (10.3)
# 32.6 (12.5)#
RV/TLC % 35.9 (8.4) 34.2 (7.3) 35.2 (8.1)
ˆ
41.0 (9. 5)#
TLC % 104.7 (14.2) 100.8 (12.8) 107. 8 (13.9)# 113.5 (13.5)#
RV % 111.4 (35.2) 101.6 (8.0) 111.2 (33.2)# 136.7 (40.9)#
Kco [mmol/min/kPa/l] 87.1 (17.4) 92.2 (15.0) 81.3 (15.7)# 77. 7 (19.3)#
TLco [mmol/min/kPa] 8.4 (1.9) 8.8 (1.8) 8.0 (2.0)
ˆ
7.4 (2.1)
Cough, % (n) 28.4 (315) 23.4 (154) 31.0 (67)# 44.8 (99)#
mucus, % (n) 26.3 (290) 21.9 (147) 25.9 (56)
ˆ
40.3 (89)#
Dyspnea, % (n) 24.7 (272) 20.4 (137) 21.8 (47)# 42.5 (94)#
Wheezing, % (n) 18.3 (202) 14.3 (96) 18.1 (39)# 33.5 (74)#
Univariate analysis with the group FEV1/FVC .70% as reference.ˆp ,0.05- .0.001
# p,0.001
doi:10.1371/journal.pone.0065177.t001
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and gas trapping on CT than those without airflow limitation,
even after extensive correction for confounders.
In the current debate on the most appropriate threshold of
FEV1/FVC for diagnosing airflow limitation the major problem is
in those subjects with indeterminate outcomes, i.e. affected
according to the fixed threshold but not-affected according to
the LLN. Therefore the current study population of relatively
healthy, but former and current smokers is well-suited as large
number of in-between subjects were included. Those with evident
airflow limitation obviously do not form a problem. In a primary
care population presenting with chronic cough it has been shown
that the fixed value of 70% has better diagnostic values than the
LLN in diagnosing COPD. [19] In that study a panel diagnosis of
COPD was used as the gold standard taking in account the FEV1/
FVC value with other relevant clinical factors.
In theory, the most appropriate threshold for FEV1/FVC in
diagnosing COPD should have the highest sensitivity and
specificity as possible. Unfortunately, without a real gold standard
for COPD calculating these numbers is not possible and a true
comparison of the fixed value and LLN are not possible. We know
from studies that using the 70% value diagnoses a larger number
of subjects with COPD than when using the LLN. [20,21]
Nonetheless, when choosing a threshold of airflow limitation it at
the least should discriminate between subjects with the structural
lung changes (emphysema, airway wall thickening) causing the
airflow limitation and subjects without.
The results of this study show that sole use of spirometry to
diagnose COPD is not ideal. COPD is a complex disease resulting
from multiple structural lung changes which not all are caught
entirely by the FEV1/FVC. Airflow limitation in COPD is caused
by two main sites in the lungs; the small airways and the lung
parenchyma. [4] In small airways disease the resistance is
increased causing airflow limitation. Emphysematous lung paren-
chyma destructions decrease the lung compliance, i.e. elastic recoil
force, which also causes airflow limitation. Both entities usually to
a greater or lesser extent coincide. Quantitative chest CT has
shown to be a promising tool in detection and quantification of
both small airway disease and emphysema. In the current study we
have used quantitative CT to show that also in subjects regarded
as affect by the 70% criterion, but not affected by the LLN
criterion, measures of small airway disease and emphysema are
significantly higher compared to healthy subjects.
The in-between subjects in this study had significantly more
structural lung changes than those without airflow limitation. This
is in concurrence with results from Mannino et al. showing that
participants of the Third National Health and Nutrition Exam-
ination Survey (NHANES III) with an FEV1/FVC ,70% but
.LLN, comparable to the in-between group in our study, had
significantly higher rates of hospitalization and mortality. [22]
Another large study reported that the in-between group had a
significantly larger consumption of health-care resources. [23] In
addition to pulmonary manifestations, it has been reported that
participants of the population based Burden of Obstructive Lung
Disease (BOLD) study with an FEV1/FVC ,70% but .LLN
have higher degrees of relevant co morbidities. [24] Yet another
study showed that subjects in the in-between group had a worse
self-reported quality of life. [25] Taken together with the results of
the current study it at the least is questionable whether ignoring
patients with an in-between FEV1/FVC ratio is acceptable.
Table 2. Degree of structural CT changes (emphysema. airway wall thickening and gas trapping) for the total population and
stratified by classification of airflow limitation.
Total, n =1,108 FEV1/FVC .70%, n=671
FEV1/FVC ,70%, but.LLN,
n=216
FEV1/FVC ,70%, and ,LLN,
n =221
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
15th percentile 2908.1 (18.9) 2902.6 (17.9) 2912.4 (15. 5)# 2921.1 (18.6)#
log950% 20.22 (1.14) 20.61 (0.93) 0.21 (0.95)# 0.76 (1.23)#
E/I-ratio% 83.70 (6.2) 81.67 (5.9) 85.53 (4.9)# 88.73 (4.7)#
Pi10 [millimeters] 2.43 (0.51) 2.28 (0.42) 2.51 (0.49)# 2.79 (0.56)#
Univariate analysis with the group FEV1/FVC .70% as reference.
# p,0.001. Log950%= log-transformed percentage of voxels below HU -950. E/I-ratio% = expiratory
mean lung density in HU divided by the inspiratory mean lung density in HU expressed as a percentage. Pi10 = the square root of wall area for a theoretical airway with
10mm lumen perimeter.
doi:10.1371/journal.pone.0065177.t002
Table 3. Multivariate analysis of mean (95% confidence interval) differences in structural CT changes (emphysema. airway wall
thickening and gas trapping) according to classification of airflow limitation correcting for age, height, BMI, packyears and
respiratory symptoms.
FEV1/FVC ,70%, but.LLN FEV1/FVC ,70%, and ,LLN
15th percentile 28.1 (210.9–25.3)# 15th percentile 216.45 (219.36–213.5) #
log950% 0.58 (0.43–0.73)# log950% 1.37 (1.25–1.56)#
E/I-ratio% 3.25 (2.32–4.27)# E/I-ratio% 6.27 (5.32–7.22)#
Pi10 [millimeters] 0.22 (0.14–0.29)# Pi10 [millimeters] 0.51 (0.43–0.59)#
The group FEV1/FVC .70% was used as reference.
# p,0.001 Log950%= log-transformed percentage of voxels below HU -950. E/I-ratio%= expiratory mean lung
density in HU divided by the inspiratory mean lung density in HU expressed as a percentage. Pi10 = the square root of wall area for a theoretical airway with 10 mm
lumen perimeter.
doi:10.1371/journal.pone.0065177.t003
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Importantly, participants with airflow limitation according to
either the fixed value of 70% or the LLN had not only more
structural CT changes but also significantly lower diffusion testing
outcomes. Our data confirms previous physiological findings on
pulmonary gas exchange abnormalities in subjects with mild
COPD. [26,27] Our data support the findings that in mild lung
function abnormalities not only lung mechanics are affected, but
also pulmonary gas exchange. [27,28].
To our knowledge, no studies yet assessed the difference in
structural lung changes according to classification of airflow
limitation in current and former smokers. The strength of the
current study is detailed characterization of CT quantified
structural lung changes (emphysema, airway wall thickness and
gas trapping). One of the limitations of the current study is the use
of pre-bronchodilator spirometry in the absence of post-broncho-
dilator values. This may have resulted in a higher percentage of
participants with airflow limitation that actually could be lower.
There is however evidence that most subjects will change from
limitation status based on non-significant changes in lung function
parameters. [20] Secondly, no females were included which is
especially unfortunate because the incidence of COPD is rising in
females. A previous study showed that females generally have less
emphysema and airway wall thickening when compared to males.
[29] Future studies should also aim to include females to elucidate
whether there is a difference in the presence of structural lung
changes according to airflow limitation classification. Finally, only
relatively healthy smokers, with no or mild COPD, were included,
and no participants with moderate to severe COPD. However,
these relatively healthy smokers are the ones most at interest for
the assessment of early structural lung changes, some which not yet
show lung function abnormalities.
In conclusion, our study showed that relatively healthy (heavy)
former and current smokers with an FEV1/FVC ,70%, but
above the LLN, already have a lower pulmonary diffusion capacity
and show significantly more structural lung changes on CT
compared to subjects without airflow limitation. The current
observations at the least questions the notion that using the 70%
threshold of FEV1/FVC for diagnosing airflow limitation is
inappropriate and is causing an over diagnosis of COPD.
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